Purpose-built, high-precision MRD testing
Exquisite sensitivity
Haystack MRD™
Minimal residual disease (MRD) testing demands the most sensitive ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after definitive surgery.
Residual disease detection
Go beyond standard risk assessment for adjuvant chemotherapy guidance to confidently treat the right person at the right time.
Treatment response assessment
Track ctDNA levels during adjuvant chemotherapy to monitor treatment response.
Disease recurrence surveillance
Detect disease relapse earlier than imaging.
Transformative precision
Dive deeper
Haystack Oncology was founded to dramatically improve patient outcomes by helping doctors optimize treatment strategies using transformative precision oncology. Learn how we support clinicians and biopharma in our mission by providing better MRD testing for better clinical management and therapeutic development.
The difference
Why Haystack MRD
Confident MRD results
Ultrasensitive ctDNA testing delivers the insights you need to make confident treatment decisions.
Transformative technology
Packed with the power of Quest
Haystack MRD offers end-to-end MRD test reliability, powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, and technology. Plus, the transition between Haystack MRD and Quest’s other advanced oncology testing is seamless for easier, more streamlined patient care. Visit questdiagnostics.com to learn more.
Haystack MRD
In the news
Haystack MRD™ at SITC 2024
Haystack MRD™ at Advancing Precision Medicine 2024
